Amgen prepares to appeal European rejection of Vectibix

Amgen is planning to appeal a decision by the European Committee for Medicinal Products for Human Use to reject Vectibix for use against colorectal cancer that has spread to other parts of the body and not responded to chemotherapy. The FDA approved Vectibix last September and the biotech giant believes that its data on progression-free survival will ultimately win over the Europeans.

- here's the AP's report on Amgen

Related Story:
Vectibix delivers positive Phase III data. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.